All In Biotech

Drug Trial Radar · NCT07758634

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

69

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Jul 1, 2028

Study completion Jul 1, 2029

Sponsor

Lead sponsor
CRISPR Therapeutics AGIndustry
Sponsor type
Industry
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Conditions

  • Hypertension

Interventions

  • CTX340Drug

    CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.

  • PlaceboDrug

    One of the arms in Phase 2 will be placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of dose-limiting toxicities (DLTs)Time frame: Up to 12 months
  2. Phase 2: Percentage change in circulating angiotensinogen (AGT) concentration from baselineTime frame: Through 6 months of follow-up.

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Flourish Research - Jacksonville

    Jacksonville, Florida · Recruiting

  • Flourish Research - Orlando

    Orlando, Florida · Recruiting

  • United Medical Research (Progressive Research)

    Port Orange, Florida · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Duke

    Durham, North Carolina · Recruiting

  • Peters Medical Research

    High Point, North Carolina · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • Monash Medical Center

    Melbourne, Australia · Recruiting

  • Richmond Pharmacology

    London, United Kingdom · Recruiting

  • University Hospitals Birmingham

    Birmingham, England, United Kingdom · Recruiting

  • Royal Papworth Hospital

    Cambridge, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.